Literature DB >> 17826782

Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease.

Jun Wang1, Ah Siew Sim, Xing Li Wang, Chris Salonikas, Mary Moriatis, Daya Naidoo, David E L Wilcken.   

Abstract

OBJECTIVE: While renal failure greatly increases coronary risk, mild renal impairment is not usually considered a major risk factor. To explore this we assessed relations between measures of mild impairment of renal function and coronary artery disease (CAD) together with other risk factors. METHODS AND
RESULTS: In 408 consecutive patients aged 75 years or less with angiographically defined normal or obstructed coronary arteries and an estimated glomerular filtration rate (eGFR) >45 mL/min per 1.73 m(2), we assessed relations between severity of CAD and levels of plasma cystatin C, creatinine, eGFR, lipid profile, C-reactive protein (CRP), homocysteine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA). With univariate ANOVA, the severity of CAD was significantly associated with all indices of renal function: increased plasma cystatin C (p=0.003) and creatinine (p=0.004) and decreased eGFR (p=0.008). An elevated plasma cystatin C was associated with increases in ADMA, SDMA, CRP, homocysteine and age. ADMA, SDMA, CRP and homocysteine levels were not associated with CAD severity. eGFR was negatively associated only with SDMA and homocysteine. In multivariate analysis, increased plasma cystatin C predicted both the occurrence and the severity of CAD more strongly than other measures of renal function.
CONCLUSIONS: We conclude that mild renal impairment detected by elevated cystatin C is associated with both the occurrence and the severity of CAD, independent of the other risk factors we measured and that mild renal impairment results in increased plasma levels of homocysteine, ADMA and SDMA. Our findings suggest a possible mechanistic link between CAD and mild renal impairment in which cystatin C may serve as an early marker for CAD and may also participate directly in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826782     DOI: 10.1016/j.atherosclerosis.2007.07.034

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  19 in total

1.  Levels of cathepsins in acute myocardial infarction.

Authors:  Kavita K Shalia; Manoj R Mashru; Vinod K Shah; Surendra L Soneji; Satchidanand Payannavar
Journal:  Indian Heart J       Date:  2012 May-Jun

2.  Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus.

Authors:  R Lertnawapan; A Bian; Y H Rho; P Raggi; A Oeser; J F Solus; T Gebretsadik; A Shintani; C M Stein
Journal:  Lupus       Date:  2011-11-09       Impact factor: 2.911

3.  Serum cystatin C as a predictor for cardiovascular events in end-stage renal disease patients at the initiation of dialysis.

Authors:  Min Ji Shin; Sang Heon Song; Ihm Soo Kwak; Soo Bong Lee; Dong Won Lee; Eun Young Seong; Il Young Kim; Harin Rhee; Naria Lee
Journal:  Clin Exp Nephrol       Date:  2012-01-26       Impact factor: 2.801

4.  The potential of Cystatin C and small dense LDL as biomarkers of coronary artery disease risk in a young Indian population.

Authors:  Anjali Manocha; Flora Gupta; Rajneesh Jain; Seema Bhargava; Mamta Kankra; Sabari Das; L M Srivastava
Journal:  Mol Cell Biochem       Date:  2013-12-20       Impact factor: 3.396

5.  Renal impairment caused by chronic occupational chromate exposure.

Authors:  Tiancheng Wang; Guang Jia; Ji Zhang; Yanhui Ma; Weiyue Feng; Lanzheng Liu; Ning Zhang; Lei Yan; Xiang Wang; Xueyan Zhang; Zihong Liu; Xianmei Du; Sen Zhen
Journal:  Int Arch Occup Environ Health       Date:  2010-08-18       Impact factor: 3.015

6.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

7.  Are levels of NT-proBNP and SDMA useful to determine diastolic dysfunction in chronic kidney disease and renal transplant patients?

Authors:  Lidija Memon; Vesna Spasojevic-Kalimanovska; Natasa Bogavac Stanojevic; Jelena Kotur-Stevuljevic; Sanja Simic-Ogrizovic; Vojislav Giga; Violeta Dopsaj; Zorana Jelic-Ivanovic; Slavica Spasic
Journal:  J Clin Lab Anal       Date:  2013-11       Impact factor: 2.352

8.  AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.

Authors:  Mina Amir; Sally I Hassanein; Mohamed F Abdel Rahman; Mohamed Z Gad
Journal:  Mol Biol Rep       Date:  2018-10-03       Impact factor: 2.316

9.  Genetic polymorphisms involved in folate metabolism and concentrations of methylmalonic acid and folate on plasma homocysteine and risk of coronary artery disease.

Authors:  Patrícia Matos Biselli; Alexandre Rodrigues Guerzoni; Moacir Fernandes de Godoy; Marcos Nogueira Eberlin; Renato Haddad; Valdemir Melechco Carvalho; Hélio Vannucchi; Erika Cristina Pavarino-Bertelli; Eny Maria Goloni-Bertollo
Journal:  J Thromb Thrombolysis       Date:  2009-03-13       Impact factor: 2.300

10.  Adropin is associated with hyperhomocysteine and coronary atherosclerosis.

Authors:  Liang-Ping Zhao; Tao You; Siew-Pang Chan; Jian-Chang Chen; Wei-Ting Xu
Journal:  Exp Ther Med       Date:  2015-12-23       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.